Team:Tsinghua/Introduction

From 2014.igem.org

(Difference between revisions)
Line 70: Line 70:
<section>
<section>
<h2>Abstract</h2>
<h2>Abstract</h2>
-
<p>&nbsp;&nbsp;&nbsp;&nbsp;<i><b> Type I diabetes mellitus </b></i> (T1DM) affects more than 17 million people worldwide, and current treatments for T1DM, known as <i><b> insulin therapy </b></i>, require continued insulin injection, diet control, and constant monitoring of blood sugar. <i><b> Gene therapy </b></i> methods that restore insulin production in non-pancreatic cells might provide a <i><b> one-shot cure </b></i> for T1DB. We propose a gene therapy for T1DM using an <i><b> adeno-associated viral </b></i> (AAV) vector that transfects somatic cells with an insulin gene controlled by a glucose-sensitive promoter, thus potentially restoring <i><b> glucose-dependent </b></i> insulin production in diabetic patients. Preliminary tests are conducted on cell lines to assess the efficiency of the therapy.</p>
+
<p>&nbsp;&nbsp;&nbsp;&nbsp;<i><b> Type I diabetes mellitus </b></i> (T1DM) affects more than 17 million people worldwide, and current treatments for T1DM, known as <i><b> insulin therapy </b></i>, require continued insulin injection, diet control, and constant monitoring of blood sugar. <i><b> Gene therapy </b></i> methods that restore insulin production in non-pancreatic cells might provide a <i><b> one-shot cure </b></i> for T1DB. We propose a gene therapy for T1DM using an <i><b> adeno-associated viral </b></i> (AAV) vector that transfects somatic cells with an insulin gene controlled by a glucose-sensitive promoter, thus potentially restoring <i><b> glucose-regulated </b></i> insulin production in diabetic patients. Preliminary tests are conducted on cell lines to assess the efficiency of the therapy.</p>
</section>
</section>
<section><p>&nbsp;</p></section>
<section><p>&nbsp;</p></section>

Revision as of 16:41, 17 October 2014

Team Tsinghua 2014 Return to iGEM 2014

Introduction: Overview

Abstract

     Type I diabetes mellitus (T1DM) affects more than 17 million people worldwide, and current treatments for T1DM, known as insulin therapy , require continued insulin injection, diet control, and constant monitoring of blood sugar. Gene therapy methods that restore insulin production in non-pancreatic cells might provide a one-shot cure for T1DB. We propose a gene therapy for T1DM using an adeno-associated viral (AAV) vector that transfects somatic cells with an insulin gene controlled by a glucose-sensitive promoter, thus potentially restoring glucose-regulated insulin production in diabetic patients. Preliminary tests are conducted on cell lines to assess the efficiency of the therapy.

 

Background

Retrieved from "http://2014.igem.org/Team:Tsinghua/Introduction"